Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1018
- Registration Number
- NCT00170963
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Fluvastatin in the Therapy of Acute Coronary Syndrome
Phase 4
Completed
- Conditions
- Coronary DiseaseMyocardial Infarction
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-07-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1000
- Registration Number
- NCT00171275
- Locations
- 🇨🇿
Novartis, Praha, Czech Republic
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
Phase 3
Terminated
- Conditions
- Hypertension
- Interventions
- Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafterDrug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 11506
- Registration Number
- NCT00170950
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇩🇰sites in Denmark, Denmark, Denmark
🇫🇮sites in Finland, Finland, Finland
Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid
Phase 4
Completed
- Conditions
- Breast Cancer With Metastatic Bone Disease
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 116
- Registration Number
- NCT00172029
- Locations
- 🇹🇷
Novartis Investigative Site, Trabzon, Turkey
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00166725
- Locations
- 🇮🇹
Orbassano, Orbassano, Italy
Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
Phase 3
Completed
- Conditions
- Osteoarthritis, Hip
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1200
- Registration Number
- NCT00154219
- Locations
- 🇺🇸
For US Site Information, contact Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇬🇧Various Sites, Multiple Cities, United Kingdom
Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
Phase 4
Completed
- Conditions
- Renal Transplantation
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00154310
- Locations
- 🇨🇭
Novartis Investigational Sites, Bern, Switzerland
🇨🇭Novartis Pharma AG, Basel, Switzerland
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
Phase 4
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 55
- Registration Number
- NCT00154323
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
Phase 3
Completed
- Conditions
- Organ Transplantation, Renal Transplantation
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 114
- Registration Number
- NCT00154284
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Phase 4
Completed
- Conditions
- Conduct Disorder
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT00154362